Henry Schein (NASDAQ:HSIC) Price Target Raised to $87.00 at Leerink Partners

Henry Schein (NASDAQ:HSIC) had its target price lifted by Leerink Partners from $75.00 to $87.00 in a research note released on Tuesday morning, Marketbeat reports. They currently have a market perform rating on the stock.

Several other research firms have also recently commented on HSIC. JPMorgan Chase & Co. raised their target price on Henry Schein from $76.00 to $78.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Mizuho set a $81.00 price target on Henry Schein and gave the stock a “neutral” rating in a report on Tuesday, January 20th. Barclays assumed coverage on shares of Henry Schein in a research report on Monday, December 8th. They set an “overweight” rating and a $86.00 price objective for the company. Barrington Research set a $79.00 target price on shares of Henry Schein and gave the company an “outperform” rating in a research report on Wednesday, November 5th. Finally, Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Henry Schein currently has an average rating of “Hold” and a consensus target price of $79.75.

Henry Schein Trading Up 3.5%

HSIC opened at $83.35 on Tuesday. Henry Schein has a twelve month low of $60.56 and a twelve month high of $89.29. The company has a fifty day moving average of $77.56 and a 200-day moving average of $71.90. The stock has a market cap of $9.81 billion, a PE ratio of 26.38, a price-to-earnings-growth ratio of 2.40 and a beta of 0.88. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. The business had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same quarter in the previous year, the business earned $1.19 earnings per share. Henry Schein’s revenue for the quarter was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, sell-side analysts predict that Henry Schein will post 4.74 EPS for the current year.

Hedge Funds Weigh In On Henry Schein

Several large investors have recently added to or reduced their stakes in HSIC. CYBER HORNET ETFs LLC bought a new stake in Henry Schein during the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc bought a new stake in Henry Schein during the second quarter worth $27,000. Flagship Harbor Advisors LLC bought a new stake in Henry Schein during the fourth quarter worth $30,000. Federated Hermes Inc. purchased a new stake in Henry Schein in the 4th quarter valued at $32,000. Finally, Los Angeles Capital Management LLC bought a new position in Henry Schein during the 4th quarter valued at $37,000. Institutional investors own 96.62% of the company’s stock.

Key Headlines Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q4 results beat consensus — EPS $1.34 vs. $1.30 estimate and revenue $3.44B vs. $3.34B, with revenue up ~7.7% year‑over‑year, validating the quarter’s top‑line strength. Henry Schein beats estimates on earnings and revenue
• Positive Sentiment: Management highlighted record sales growth and stabilizing demand for dental and medical equipment, supporting the revenue beat and near‑term recovery narrative. Henry Schein Inc (HSIC) Q4 2025 Earnings Call Highlights: Record Sales Growth and Strategic …
• Positive Sentiment: FY‑2026 guidance set to $5.230–$5.370 EPS and revenue $13.6B–$13.8B — roughly in line with consensus EPS and slightly above revenue expectations, giving reassurance on forward visibility. Press Release / Slide Deck (Q4 FY2025)
• Positive Sentiment: Analyst sentiment turned firmer — Robert W. Baird upgraded HSIC to “outperform” with a $100 PT and Leerink raised its target to $87, adding buy‑side traction and supporting the stock’s move higher. Henry Schein Stock Hits 52-Week High – Here’s Why
• Neutral Sentiment: Shares reached a 52‑week high and traded with elevated volume after the print and upgrades, reflecting the market’s positive reception. Henry Schein Stock Hits 52-Week High – Here’s Why
• Neutral Sentiment: Full earnings call transcript and analyst summaries are available for deeper read—useful for investors who want granular color on product mix, geographic trends, and capital allocation. Henry Schein, Inc. (HSIC) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Margin pressure tempered the beat — several reports and the call noted contraction in margins (declines in profitability metrics), which could cap near‑term upside until cost trends improve. HSIC Q4 Earnings & Revenues Beat Estimates, Margins Down
• Negative Sentiment: Some commentary flagged ongoing cost and margin headwinds despite sales growth — an important watch item that could pressure margins and forward EPS if not resolved. Henry Schein Balances Strong Growth With Margin Pressure

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.